JP2020524490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524490A5 JP2020524490A5 JP2019567283A JP2019567283A JP2020524490A5 JP 2020524490 A5 JP2020524490 A5 JP 2020524490A5 JP 2019567283 A JP2019567283 A JP 2019567283A JP 2019567283 A JP2019567283 A JP 2019567283A JP 2020524490 A5 JP2020524490 A5 JP 2020524490A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- item
- coli
- promoter
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000588724 Escherichia coli Species 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 28
- 230000000813 microbial effect Effects 0.000 claims description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 12
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 claims description 8
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 101150118992 dxr gene Proteins 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 5
- 239000000854 Human Growth Hormone Substances 0.000 claims description 5
- 108010057186 Insulin Glargine Proteins 0.000 claims description 5
- 108010005714 Interferon beta-1b Proteins 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 108010010648 interferon alfacon-1 Proteins 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 102000055006 Calcitonin Human genes 0.000 claims description 4
- 108060001064 Calcitonin Proteins 0.000 claims description 4
- 102000051325 Glucagon Human genes 0.000 claims description 4
- 108060003199 Glucagon Proteins 0.000 claims description 4
- 102000018997 Growth Hormone Human genes 0.000 claims description 4
- 108010051696 Growth Hormone Proteins 0.000 claims description 4
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 4
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 4
- 108010065920 Insulin Lispro Proteins 0.000 claims description 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 4
- 102000006992 Interferon-alpha Human genes 0.000 claims description 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 4
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 4
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 4
- 101150047711 acs gene Proteins 0.000 claims description 4
- 229960004015 calcitonin Drugs 0.000 claims description 4
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
- 229960004666 glucagon Drugs 0.000 claims description 4
- 239000000122 growth hormone Substances 0.000 claims description 4
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims description 4
- 102000058004 human PTH Human genes 0.000 claims description 4
- BYMJQPSBSTWSGH-UHFFFAOYSA-N humarin Natural products OCC1OC(OCC2OC(OC(=O)c3cc(O)c(O)c(O)c3)C(O)C(O)C2O)C(O)C(O)C1OC(=O)c4cc(O)c(O)c(O)c4 BYMJQPSBSTWSGH-UHFFFAOYSA-N 0.000 claims description 4
- 229940090438 infergen Drugs 0.000 claims description 4
- 229960002068 insulin lispro Drugs 0.000 claims description 4
- 229940065638 intron a Drugs 0.000 claims description 4
- 229940060975 lantus Drugs 0.000 claims description 4
- 229940076783 lucentis Drugs 0.000 claims description 4
- 239000000199 parathyroid hormone Substances 0.000 claims description 4
- 229960001319 parathyroid hormone Drugs 0.000 claims description 4
- 108010068072 salmon calcitonin Proteins 0.000 claims description 4
- 229960004532 somatropin Drugs 0.000 claims description 4
- 229960003102 tasonermin Drugs 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- PVPAMMQRQRLZBS-UHFFFAOYSA-N 1-hydroxy-7,9-dihydro-3h-purine-2,6,8-trione Chemical compound O=C1N(O)C(=O)NC2=C1NC(=O)N2 PVPAMMQRQRLZBS-UHFFFAOYSA-N 0.000 claims description 3
- 101100056285 Escherichia coli (strain K12) ariR gene Proteins 0.000 claims description 3
- 101100126274 Escherichia coli (strain K12) iraM gene Proteins 0.000 claims description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 claims description 3
- 102000016261 Long-Acting Insulin Human genes 0.000 claims description 3
- 229940100066 Long-acting insulin Drugs 0.000 claims description 3
- 101150050866 argD gene Proteins 0.000 claims description 3
- 101150107204 asd gene Proteins 0.000 claims description 3
- 101150034124 ask gene Proteins 0.000 claims description 3
- 101150081158 crtB gene Proteins 0.000 claims description 3
- 101150000046 crtE gene Proteins 0.000 claims description 3
- 101150085103 crtY gene Proteins 0.000 claims description 3
- 101150011371 dapA gene Proteins 0.000 claims description 3
- 101150073654 dapB gene Proteins 0.000 claims description 3
- 101150064923 dapD gene Proteins 0.000 claims description 3
- 101150000582 dapE gene Proteins 0.000 claims description 3
- 101150062988 dapF gene Proteins 0.000 claims description 3
- 101150057904 ddh gene Proteins 0.000 claims description 3
- 101150056470 dxs gene Proteins 0.000 claims description 3
- 101150089768 elbB gene Proteins 0.000 claims description 3
- 101150057497 fbp gene Proteins 0.000 claims description 3
- 101150118781 icd gene Proteins 0.000 claims description 3
- 101150075592 idi gene Proteins 0.000 claims description 3
- 101150064873 ispA gene Proteins 0.000 claims description 3
- 101150000769 ispB gene Proteins 0.000 claims description 3
- 101150014059 ispD gene Proteins 0.000 claims description 3
- 101150068863 ispE gene Proteins 0.000 claims description 3
- 101150018742 ispF gene Proteins 0.000 claims description 3
- 101150081094 ispG gene Proteins 0.000 claims description 3
- 101150017044 ispH gene Proteins 0.000 claims description 3
- 101150033534 lysA gene Proteins 0.000 claims description 3
- 101150044424 lysE gene Proteins 0.000 claims description 3
- 101150088738 pckA gene Proteins 0.000 claims description 3
- 101150067708 pckG gene Proteins 0.000 claims description 3
- 101150053253 pgi gene Proteins 0.000 claims description 3
- 101150023641 ppc gene Proteins 0.000 claims description 3
- 101150096049 pyc gene Proteins 0.000 claims description 3
- 101150106048 ymgA gene Proteins 0.000 claims description 3
- 101150078419 zwf gene Proteins 0.000 claims description 3
- 101150099894 GDHA gene Proteins 0.000 claims description 2
- 229960004859 glucarpidase Drugs 0.000 claims description 2
- 108010049491 glucarpidase Proteins 0.000 claims description 2
- 101150013067 appY gene Proteins 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229940065770 humatrope Drugs 0.000 claims 1
- 229960003358 interferon alfacon-1 Drugs 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 91
- 238000004519 manufacturing process Methods 0.000 description 80
- 230000007614 genetic variation Effects 0.000 description 73
- 108090000790 Enzymes Proteins 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 22
- 238000013461 design Methods 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 17
- 238000000354 decomposition reaction Methods 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 14
- 238000006731 degradation reaction Methods 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 230000004568 DNA-binding Effects 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 10
- 239000002207 metabolite Substances 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 102000054765 polymorphisms of proteins Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000446 fuel Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 150000003384 small molecules Chemical group 0.000 description 5
- 108010029961 Filgrastim Proteins 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 229960004177 filgrastim Drugs 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 101150011432 apy gene Proteins 0.000 description 2
- 101150011633 crtI gene Proteins 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
- 208000008319 Bietti crystalline dystrophy Diseases 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515870P | 2017-06-06 | 2017-06-06 | |
| US62/515,870 | 2017-06-06 | ||
| PCT/US2018/036333 WO2018226880A1 (en) | 2017-06-06 | 2018-06-06 | A htp genomic engineering platform for improving escherichia coli |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524490A JP2020524490A (ja) | 2020-08-20 |
| JP2020524490A5 true JP2020524490A5 (https=) | 2021-07-26 |
Family
ID=62751581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567283A Pending JP2020524490A (ja) | 2017-06-06 | 2018-06-06 | Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200370058A1 (https=) |
| EP (2) | EP3485013B1 (https=) |
| JP (1) | JP2020524490A (https=) |
| KR (1) | KR20200026874A (https=) |
| CN (1) | CN110945125A (https=) |
| CA (1) | CA3064612A1 (https=) |
| ES (1) | ES2875579T3 (https=) |
| WO (1) | WO2018226880A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111615557B (zh) * | 2017-11-22 | 2025-04-18 | 国立大学法人神户大学 | 稳定且副作用少的基因组编辑用复合物和编码该复合物的核酸 |
| SG11202104409YA (en) | 2018-10-31 | 2021-05-28 | Zymergen Inc | Multiplexed deterministic assembly of dna libraries |
| CN113728106A (zh) * | 2019-03-08 | 2021-11-30 | 齐默尔根公司 | 微生物中的迭代基因组编辑 |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| US11526705B2 (en) * | 2019-04-01 | 2022-12-13 | Lg Electronics Inc. | Method of classificating outlier in object recognition and device and robot of classifying thereof |
| US20220267782A1 (en) * | 2019-06-21 | 2022-08-25 | Glycom A/S | Nucleic acid construct comprising 5' utr stem-loop for in vitro and in vivo gene expression |
| CN110272907B (zh) * | 2019-08-12 | 2021-04-23 | 华中农业大学 | 一种调控番茄茎杆发育的基因sd1及其应用 |
| GB202001211D0 (en) * | 2020-01-29 | 2020-03-11 | Imperial College Innovations Ltd | Methods |
| CN111612133B (zh) * | 2020-05-20 | 2021-10-19 | 广州华见智能科技有限公司 | 基于人脸图像多阶段关系学习的内脏器官特征编码方法 |
| CN111700075B (zh) * | 2020-06-05 | 2021-08-17 | 茂名市瑜丰沉香创意产业有限公司 | 人工结香沉香、沉香精油富集液、沉香香皂及其生产方法 |
| JPWO2022124302A1 (https=) * | 2020-12-08 | 2022-06-16 | ||
| CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
| CN113265412A (zh) * | 2021-05-20 | 2021-08-17 | 北京化工大学 | 多酶偶联定位体系及其构建方法和应用 |
| CN113393900B (zh) * | 2021-06-09 | 2022-08-02 | 吉林大学 | 基于改进Transformer模型的RNA状态推断研究方法 |
| US11530406B1 (en) | 2021-08-30 | 2022-12-20 | Sachi Bioworks Inc. | System and method for producing a therapeutic oligomer |
| US12037621B2 (en) | 2021-09-15 | 2024-07-16 | Archer-Daniels-Midland Company | Threonine production strain having attenuated expression of the yafV gene |
| CN114672505A (zh) * | 2022-03-15 | 2022-06-28 | 江苏省中国科学院植物研究所 | 一种功能性表达细胞色素p450酶的方法及其应用 |
| CN114921463B (zh) * | 2022-04-11 | 2023-12-01 | 中国农业科学院生物技术研究所 | 一种调控萜类化合物合成产量的人工非编码RNA分子CsiY及其应用 |
| CN115074410B (zh) * | 2022-06-30 | 2025-08-19 | 武汉合生科技有限公司 | 一种生物合成虾青素的方法及载体 |
| CN115992160A (zh) * | 2022-09-30 | 2023-04-21 | 倍生生物科技(深圳)有限公司 | 一种穿梭载体及其构建方法和应用 |
| CN115820703A (zh) * | 2022-12-20 | 2023-03-21 | 山东乾肽生物科技有限公司 | 利用rna环化技术制备寡肽的方法及寡肽的表达dna |
| CN116013407B (zh) * | 2022-12-26 | 2025-06-27 | 杭州智科慧创科技有限公司 | 一种基于语言模型的性质解耦蛋白质生成方法 |
| CN116504313A (zh) * | 2023-05-08 | 2023-07-28 | 暨南大学 | 基因终止子查询方法、装置、设备及可读存储介质 |
| CN117275590B (zh) * | 2023-11-10 | 2024-03-26 | 华东师范大学 | 有机固废体系中大分子的降解功能基因数据库与分析平台 |
| KR20250069469A (ko) * | 2023-11-10 | 2025-05-19 | 한국과학기술원 | TdT(Terminal deoxynucleotidyl transferase) 및 dNTP를 이용한 비번역영역 (untranslated region) 라이브러리 합성 방법 |
| CN117238380A (zh) * | 2023-11-15 | 2023-12-15 | 中国医学科学院北京协和医院 | 宏基因组病原识别的ai推荐方法、装置、设备及介质 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US72197A (en) | 1867-12-17 | Jesse h | ||
| US824A (en) | 1838-07-09 | Construction of steam-engines | ||
| US4435504A (en) | 1982-07-15 | 1984-03-06 | Syva Company | Immunochromatographic assay with support having bound "MIP" and second enzyme |
| GB8406752D0 (en) | 1984-03-15 | 1984-04-18 | Unilever Plc | Chemical and clinical tests |
| CA1303983C (en) | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
| US4855240A (en) | 1987-05-13 | 1989-08-08 | Becton Dickinson And Company | Solid phase assay employing capillary flow |
| US6060296A (en) | 1991-07-03 | 2000-05-09 | The Salk Institute For Biological Studies | Protein kinases |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6090592A (en) | 1994-08-03 | 2000-07-18 | Mosaic Technologies, Inc. | Method for performing amplification of nucleic acid on supports |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| KR100570935B1 (ko) * | 1997-01-17 | 2006-04-13 | 맥시겐, 인크. | 반복적 서열 재조합에 의한 전세포 및 유기체의 개량 방법 |
| US6326204B1 (en) * | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| JP2002503954A (ja) | 1997-04-01 | 2002-02-05 | グラクソ、グループ、リミテッド | 核酸増幅法 |
| JPH1180185A (ja) | 1997-09-05 | 1999-03-26 | Res Dev Corp Of Japan | オリゴヌクレオチドの化学合成法 |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| KR20010041088A (ko) | 1998-02-20 | 2001-05-15 | 게놈 다이내믹스 인코포레이티드 | 아연-핑거 클래스의 ｄｎａ-결합 단백질의 디자인 방법 |
| AR021833A1 (es) | 1998-09-30 | 2002-08-07 | Applied Research Systems | Metodos de amplificacion y secuenciacion de acido nucleico |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6300070B1 (en) | 1999-06-04 | 2001-10-09 | Mosaic Technologies, Inc. | Solid phase methods for amplifying multiple nucleic acids |
| US6927046B1 (en) * | 1999-12-30 | 2005-08-09 | Archer-Daniels-Midland Company | Increased lysine production by gene amplification using coryneform bacteria |
| US7785832B2 (en) * | 2000-05-09 | 2010-08-31 | HALLA Patent & Law Firm | Method of protein synthesis |
| WO2002029032A2 (en) * | 2000-09-30 | 2002-04-11 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| AU2002228841C1 (en) | 2000-12-07 | 2006-11-23 | Sangamo Biosciences, Inc | Regulation of angiogenesis with zinc finger proteins |
| US7067617B2 (en) | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
| US20070178454A1 (en) | 2002-10-21 | 2007-08-02 | Joung J K | Context sensitive paralell optimization of zinc finger dna binding domains |
| WO2005021772A1 (en) | 2003-08-29 | 2005-03-10 | Degussa Ag | Process for the preparation of l-lysine |
| EP2021489A2 (en) | 2006-05-30 | 2009-02-11 | Dow Global Technologies Inc. | Codon optimization method |
| CN101177454B (zh) * | 2007-05-09 | 2010-09-22 | 郑骏年 | Il-18突变体多肽及制备及用途 |
| US8765403B2 (en) | 2008-02-28 | 2014-07-01 | The Regents Of The University Of California | Use of synthetic scaffolds for the production of biosynthetic pathway products |
| CA2729839A1 (en) * | 2008-07-03 | 2010-01-07 | Diane Retallack | High throughput screening method and use thereof to identify a production platform for a multifunctional binding protein |
| WO2010025310A2 (en) | 2008-08-27 | 2010-03-04 | Westend Asset Clearinghouse Company, Llc | Methods and devices for high fidelity polynucleotide synthesis |
| US20100137143A1 (en) | 2008-10-22 | 2010-06-03 | Ion Torrent Systems Incorporated | Methods and apparatus for measuring analytes |
| US8783382B2 (en) | 2009-01-15 | 2014-07-22 | Schlumberger Technology Corporation | Directional drilling control devices and methods |
| EP2398915B1 (en) | 2009-02-20 | 2016-08-24 | Synthetic Genomics, Inc. | Synthesis of sequence-verified nucleic acids |
| US8574835B2 (en) | 2009-05-29 | 2013-11-05 | Life Technologies Corporation | Scaffolded nucleic acid polymer particles and methods of making and using |
| EP2395087A1 (en) | 2010-06-11 | 2011-12-14 | Icon Genetics GmbH | System and method of modular cloning |
| PL2657250T3 (pl) * | 2010-12-21 | 2018-02-28 | Cj Cheiljedang Corporation | Odmiana polipeptydu posiadającego aktywność acetylotransferazy homoseryny oraz mikroorganizm wyrażający to samo |
| US20150368639A1 (en) * | 2011-04-14 | 2015-12-24 | Ryan T. Gill | Compositions, methods and uses for multiplex protein sequence activity relationship mapping |
| AU2012249390B2 (en) * | 2011-04-27 | 2017-03-30 | Amyris, Inc. | Methods for genomic modification |
| CN102352337B (zh) * | 2011-08-03 | 2014-04-23 | 中国人民解放军军事医学科学院生物工程研究所 | 利用异源启动子控制大肠杆菌基因组n-乙酰基转移酶表达重组菌及应用 |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| EP2840140B2 (en) | 2012-12-12 | 2023-02-22 | The Broad Institute, Inc. | Crispr-Cas based method for mutation of prokaryotic cells |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| IL239344B2 (en) | 2012-12-12 | 2024-06-01 | Broad Inst Inc | Systems engineering, methods and optimal guiding components for sequence manipulation |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| CN106459995B (zh) | 2013-11-07 | 2020-02-21 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| US10815478B2 (en) | 2014-11-05 | 2020-10-27 | Illumina, Inc. | Method of sequential tagmentation with transposase compositions for reduction of insertion bias |
| US9650617B2 (en) | 2015-01-28 | 2017-05-16 | Pioneer Hi-Bred International. Inc. | CRISPR hybrid DNA/RNA polynucleotides and methods of use |
| CA2981716C (en) | 2015-04-10 | 2022-04-12 | Feldan Bio Inc. | Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| KR102356072B1 (ko) | 2015-09-10 | 2022-01-27 | 에스케이하이닉스 주식회사 | 메모리 시스템 및 그 동작 방법 |
| WO2017070598A1 (en) | 2015-10-23 | 2017-04-27 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| BR112018011503A2 (pt) * | 2015-12-07 | 2018-12-04 | Zymergen Inc | promotores da corynebacterium glutamicum |
| US11151497B2 (en) * | 2016-04-27 | 2021-10-19 | Zymergen Inc. | Microbial strain design system and methods for improved large-scale production of engineered nucleotide sequences |
| US9988624B2 (en) * | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| KR20190090081A (ko) * | 2015-12-07 | 2019-07-31 | 지머젠 인코포레이티드 | Htp 게놈 공학 플랫폼에 의한 미생물 균주 개량 |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
-
2018
- 2018-06-06 WO PCT/US2018/036333 patent/WO2018226880A1/en not_active Ceased
- 2018-06-06 JP JP2019567283A patent/JP2020524490A/ja active Pending
- 2018-06-06 US US16/620,069 patent/US20200370058A1/en not_active Abandoned
- 2018-06-06 ES ES18734715T patent/ES2875579T3/es active Active
- 2018-06-06 EP EP18734715.8A patent/EP3485013B1/en active Active
- 2018-06-06 EP EP21162339.2A patent/EP3878961A1/en not_active Withdrawn
- 2018-06-06 KR KR1020207000237A patent/KR20200026874A/ko not_active Withdrawn
- 2018-06-06 CA CA3064612A patent/CA3064612A1/en not_active Abandoned
- 2018-06-06 CN CN201880047657.XA patent/CN110945125A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524490A5 (https=) | ||
| Coco et al. | Growth factor engineering by degenerate homoduplex gene family recombination | |
| O'Maille et al. | Structure-based combinatorial protein engineering (SCOPE) | |
| AU2007287327B2 (en) | Matrix attachment regions (MARs) for increasing transcription and uses thereof | |
| CN109136248B (zh) | 多靶点编辑载体及其构建方法和应用 | |
| JP2020524493A5 (https=) | ||
| Van Tol et al. | Artificial transcription factor-mediated regulation of gene expression | |
| WO2008076368A2 (en) | Fragment-rearranged nucleic acids and uses thereof | |
| EP2921560B1 (en) | Method for synthesizing gene library using codon combination and mutagenesis | |
| Pohlschroder et al. | Haloferax volcanii: a versatile model for studying archaeal biology | |
| US20160017410A1 (en) | Highly multiplex single amino acid mutagenesis for massively parallel functional analysis | |
| US20210130809A1 (en) | Evolution-guided multiplexed dna assembly of dna parts, pathways and genomes | |
| US20110097709A1 (en) | Method for modifying a nucleic acid | |
| CN116200366B (zh) | 具有XNA合成及反转录活性的Bst DNA聚合酶突变株 | |
| CN101541959A (zh) | 用于增加转录的基质附着区（mar）及其应用 | |
| WO2006047669A2 (en) | Non-random method of gene shuffling | |
| CN113652411A (zh) | Cas9蛋白、含有Cas9蛋白的基因编辑系统及应用 | |
| CN109477134A (zh) | 转座酶竞争物控制系统 | |
| Huang et al. | Characterization of the macronuclear and micronuclear pheromone genes of Euplotes raikovi reveals the origin of the mating type genetic diversity | |
| Li et al. | Enrichment of prime-edited mammalian cells with surrogate PuroR reporters | |
| CN115052980B (zh) | 衍生自黄杆菌的基因编辑系统 | |
| KR20240095313A (ko) | Cas 단백질 또는 이의 변이체의 스크리닝 방법, 및 이를 이용하여 제조된 Cas 단백질 또는 이의 변이체 | |
| Ebner et al. | Exploiting Self-Processing 2A Peptides for Multigene Expression in Pichia pastoris | |
| EP4508220A1 (en) | Systems and methods for genome-scale targeting of functional redundancy in plants | |
| Gonzales et al. | Dgp1 and Dfp1 Are Closely Related Plasmids in theDictyosteliumDdp2 Plasmid Family |